A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Study to Evaluate the Efficacy of MK0524 to Improve Tolerability of Extended Release Niacin

Trial Profile

A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Study to Evaluate the Efficacy of MK0524 to Improve Tolerability of Extended Release Niacin

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs Niacin/laropiprant (Primary) ; Niacin
  • Indications Hypercholesterolaemia; Hyperlipidaemia
  • Focus Therapeutic Use
  • Acronyms COMPLETED
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 06 Oct 2015 Treatment table revised with an inclusion of extra placebo arm.
    • 27 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top